



**HAL**  
open science

## Comparative Metabolism of Cyclophosphamide and Ifosfamide in the Mouse Using UPLC-ESI-QTOFMS-Based Metabolomics

Fei Li, Andrew D. Patterson, Constance C. Höfer, Kristopher W. Krausz, Frank J. Gonzalez, Jeffrey R. Idle

► **To cite this version:**

Fei Li, Andrew D. Patterson, Constance C. Höfer, Kristopher W. Krausz, Frank J. Gonzalez, et al.. Comparative Metabolism of Cyclophosphamide and Ifosfamide in the Mouse Using UPLC-ESI-QTOFMS-Based Metabolomics. *Biochemical Pharmacology*, 2010, 80 (7), pp.1063. 10.1016/j.bcp.2010.06.002 . hal-00614639

**HAL Id: hal-00614639**

**<https://hal.science/hal-00614639>**

Submitted on 14 Aug 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Accepted Manuscript

Title: Comparative Metabolism of Cyclophosphamide and Ifosfamide in the Mouse Using UPLC-ESI-QTOFMS-Based Metabolomics

Authors: Fei Li, Andrew D. Patterson, Constance C. Höfer, Kristopher W. Krausz, Frank J. Gonzalez, Jeffrey R. Idle



PII: S0006-2952(10)00392-8  
DOI: doi:10.1016/j.bcp.2010.06.002  
Reference: BCP 10583

To appear in: *BCP*

Received date: 25-4-2010  
Revised date: 27-5-2010  
Accepted date: 3-6-2010

Please cite this article as: Li F, Patterson AD, Höfer CC, Krausz KW, Gonzalez FJ, Idle JR, Comparative Metabolism of Cyclophosphamide and Ifosfamide in the Mouse Using UPLC-ESI-QTOFMS-Based Metabolomics, *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2010.06.002

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Comparative Metabolism of Cyclophosphamide and Ifosfamide in the Mouse Using UPLC-ESI-QTOFMS-Based Metabolomics

Fei Li<sup>a</sup>, Andrew D. Patterson<sup>a</sup>, Constance C. Höfer<sup>b</sup>, Kristopher W. Krausz<sup>a</sup>,  
Frank J. Gonzalez<sup>a</sup>, Jeffrey R. Idle<sup>a,c,\*</sup>

<sup>a</sup>Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National  
Institutes of Health, Bethesda, MD 20852, United State

<sup>b</sup>DMPKORE, Hindenburgstrasse 17a, D-85057 Ingolstadt, Germany

<sup>c</sup>Institute of Pharmacology, First Faculty of Medicine, Albertov 4, 128 00 Praha 2, Charles  
University, Praha, Czech Republic

\*Corresponding author: Professor JR Idle, Institute of Pharmacology, First Faculty of  
Medicine, Charles University, Albertov 4, 128 00 Praha 2, Czech Republic. Tel: +420 603  
484 583, Fax: +420 220 912 140, Email: [idlejr@mail.nih.gov](mailto:idlejr@mail.nih.gov).

Email address: [lif3@mail.nih.gov](mailto:lif3@mail.nih.gov) (F. Li), [andrewpatterson@mail.nih.gov](mailto:andrewpatterson@mail.nih.gov) (A. D. Patterson),  
[c.hoefer@dmpkore.com](mailto:c.hoefer@dmpkore.com) (C. C. Höfer), [krauszk@intra.nci.nih.gov](mailto:krauszk@intra.nci.nih.gov) (K. W. Krausz),  
[fjgonz@helix.nih.gov](mailto:fjgonz@helix.nih.gov) (F. J. Gonzalez), [idlejr@mail.nih.gov](mailto:idlejr@mail.nih.gov) (J. R. Idle)

**ABSTRACT**

1  
2  
3 Ifosfamide (IF) and cyclophosphamide (CP) are common chemotherapeutic agents.  
4  
5  
6 Interestingly, while the two drugs are isomers, only IF treatment is known to cause  
7  
8 nephrotoxicity and neurotoxicity. Therefore, it was anticipated that a comparison of IF and  
9  
10 CP drug metabolites in the mouse would reveal reasons for this selective toxicity. Drug  
11  
12 metabolites were profiled by ultra-performance liquid chromatography-linked electrospray  
13  
14 ionization quadrupole time-of-flight mass spectrometry (UPLC-ESI-QTOFMS), and the  
15  
16 results analyzed by multivariate data analysis. Of the total 23 drug metabolites identified by  
17  
18 UPLC-ESI-QTOFMS for both IF and CP, five were found to be novel. Ifosfamide  
19  
20 preferentially underwent *N*-dechloroethylation, the pathway yielding 2-chloroacetaldehyde,  
21  
22 while cyclophosphamide preferentially underwent ring-opening, the pathway yielding  
23  
24 acrolein (AC). Additionally, *S*-carboxymethylcysteine and thiodiglycolic acid, two  
25  
26 downstream IF and CP metabolites, were produced similarly in both IF- and CP-treated mice.  
27  
28 This may suggest that other metabolites, perhaps precursors of thiodiglycolic acid, may be  
29  
30 responsible for IF encephalopathy and nephropathy.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 **Keywords:** Ifosfamide; Cyclophosphamide; Metabolomics; Ultra-performance liquid  
46  
47 chromatography; Time-of-flight mass spectrometry; Tandem mass spectrometry  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 1. Introduction

1  
2  
3 Cyclophosphamide (CP) and ifosfamide (IF) are isomeric oxazaphosphorine cytostatic  
4  
5  
6 drugs used widely in the chemotherapy of various cancers. CP was developed over 50 years  
7  
8  
9 ago as a innovative example of a pro-drug that might be transported to the tumor and then  
10  
11  
12 activated by tumor-specific enzymes, a strategy that had proven valuable for the treatment of  
13  
14  
15 prostate carcinoma with stilbestrol diphosphate [1]. High tumor expression and activity of  
16  
17  
18 phosphoramidase was the rational design principle [2] that lead to the incorporation of the  
19  
20  
21 highly cytotoxic nornitrogen mustard (NNM) into a stable and apparently inert  
22  
23  
24 oxazaphosphorine ring (Fig. 1A). It soon transpired that NNM was generated only in trace  
25  
26  
27 amounts but rather CP was converted in the liver into a transported metabolite that could be  
28  
29  
30 readily taken up by tumors [3]. A somewhat complex hepatic metabolic scheme gradually  
31  
32  
33 unfolded with CP converted to 4-hydroxycyclophosphamide (4OHCP) [4], which in turn  
34  
35  
36 tautomomerized to aldophosphamide (AP) [5] that  $\beta$ -eliminated AC [6-7] to yield  
37  
38  
39 phosphoramidate mustard (PM) [7-8]. This pathway can readily be reconciled with other  
40  
41  
42 observed metabolites of CP, such as 4-oxocyclophosphamide (4-ketocyclophosphamide;  
43  
44  
45 4OCP) [9], iminocyclophosphamide (ICP) [10], and carboxyphosphamide (CXP) [11] (Fig.  
46  
47  
48 1A). Both AP [7] and PM [11] were postulated as transport forms of CP. Ifosfamide (IF) was  
49  
50  
51 developed a decade after CP [12] and its metabolic transformation was reported to bear  
52  
53  
54 similarities to its isomer CP (Fig. 1B). Specifically, phenobarbital-induced rat liver  
55  
56  
57 microsomes converted IF to AC [7, 13] after the prior formation of 4-hydroxyifosfamide  
58  
59  
60 (4OHIF) [7], which was later reported to be in equilibrium with its tautomer aldoifosfamide  
61  
62  
63 (AIF) [14]. However, a major metabolic pathway for IF was side-chain dealkylation to yield  
64  
65

1 2- and 3-dechloroethylifosfamide (2-DCIF and 3-DCIF), both *in vitro* [7] and *in vivo* [15],  
2  
3 together with 2-chloroacetaldehyde (CAL) [16] and 2-chloroethylamine (CEA) [17-18].  
4  
5  
6 These two-carbon metabolites had been reported at only low levels in CP-treated rodents [11,  
7  
8  
9 19-20]. Later reports demonstrated side-chain dealkylation yielding 2-DCIF and 3-DCIF as a  
10  
11 major pathway of IF metabolism in both pediatric [21-23] and adult patients [24-26]. While  
12  
13 the systemic toxicity of the aldehyde product of CP and IF metabolism AC had been  
14  
15 mitigated by the introduction of mesna [27-28], the issue of host toxicity due to CAL was not  
16  
17 immediately addressed [16].  
18  
19  
20  
21

22  
23 The differential metabolism of CP and IF most likely plays a central role in the differing  
24  
25 toxicity profiles of these isomeric drugs. While the general pattern of intact  
26  
27 oxazaphosphorine metabolites is similar for CP and IF, a key difference is the number and  
28  
29 abundance of two-carbon metabolites that derive from side-chain dealkylation. It was  
30  
31 proposed that CAL underlies both the neurotoxicity [16, 29-30] and nephrotoxicity [31] of IF.  
32  
33  
34 Additionally, CEA was proposed as a toxic metabolite [29-30] and has been reported to  
35  
36 derive directly from IF by chemical hydrolysis and also reacting with bicarbonate to form  
37  
38 1,3-oxazolidin-2-one [17]. CAL has been reported to be converted to 2-chloroacetic acid  
39  
40 (CAA) by human kidney [31] and rabbit heart [32]. In turn, CAA may react with cellular  
41  
42 thiols to yield *S*-carboxymethylcysteine (SCMC) and its metabolite thiodiglycolic acid  
43  
44 (TDGA) [15] (Fig. 1B). Other cysteine derived metabolites have also been observed [32].  
45  
46  
47  
48  
49  
50  
51  
52  
53 What role this panoply of small IF metabolites plays in the selective toxicity and efficacy of  
54  
55  
56 IF is poorly understood.  
57  
58  
59  
60  
61  
62  
63  
64  
65

1           What is clear is that CP and IF are two potent drugs which are inactive *per se* and whose  
2  
3 effects on both the tumor and the host are determined by metabolism. Despite the large  
4  
5 number of published studies on the metabolism of CP and IF both *in vitro* and *in vivo* and in a  
6  
7 variety of species including Man (Table 1), a comprehensive comparative analysis of their  
8  
9 metabolism is indicated. We have chosen to do this in the mouse for the sole reason that such  
10  
11 a study lends itself to further investigation in animals humanized for various metabolic  
12  
13 enzymes and the nuclear receptors that regulate their tissue expression [33]. We have also  
14  
15 employed ultra-performance chromatography-linked electrospray ionization quadrupole time-  
16  
17 of-flight mass spectrometry (UPLC-ESI-QTOFMS), which has proven successful in studies  
18  
19 involving metabolomic protocols to uncover unforeseen drug metabolites of PhIP [34],  
20  
21 melatonin [35], aminoflavone [36], acetaminophen [37], and the areca alkaloids [38-39].  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 2. Materials and Methods

### 2.1. Materials

IF (ifosfamide), CP (cyclophosphamide), SCMC (*S*-carboxymethylcysteine), TDGA (thiodiglycolic acid), and 4-nitrobenzoic acid were purchased from Sigma-Aldrich (St. Louis, MO). Solvents and other chemicals were of the highest grade commercially available.

### 2.2. Animals and treatments

Male C57BL/6 mice were obtained from the NCI-Frederick Animal Production Program. Mice were maintained under standard 12 h light/12 h dark cycle with water and chow provided *ad libitum*. Handling and treatment was in accordance with an animal study protocol approved by the National Cancer Institute Animal Care and Use Committee. IF (50 mg/kg) and CP (50 mg/kg) were dissolved in saline solution and administered by intraperitoneal injection. Control mice were treated with saline alone. Urine (24 h) samples were collected from mice housed individually in glass metabolic chambers (Jencons, Leighton Buzzard, UK).

### 2.3. UPLC-ESI-QTOFMS profiling of urinary metabolites

Urine samples were prepared by mixing 10  $\mu$ l of urine with 90  $\mu$ l of 50% aqueous acetonitrile and centrifuging at  $18,000 \times g$  for 10 min to remove protein and particulates. A 5  $\mu$ l aliquot of supernatant was injected into a Waters UPLC-ESI-QTOFMS system (Milford, MA). An Acquity UPLC BEH C18 column (Waters) was used to separate chemical components, including IF, CP and their metabolites. The mobile phase was comprised of



0.1% formic acid (A) and acetonitrile containing 0.1% formic acid (B). A 0.5 ml/min flow rate was maintained during a 10 min run. The QTOF Premier mass spectrometer was operated in electrospray positive ionization mode (ESI+). Capillary voltage and cone voltage were maintained at 3 kV and 20 V, respectively. Source temperature and desolvation temperature were set at 120 °C and 350 °C, respectively. Nitrogen was used as both cone gas (50 l/h) and desolvation gas (600 l/h), and argon was used as collision gas. Sulfadimethoxine was used as the lock mass ( $m/z$  311.0814<sup>+</sup>) for accurate mass calibration in real time. As for MS/MS fragmentation of target ions, collision energy ranging from 10 to 40 eV was applied. Mass chromatograms and mass spectral data were acquired using MassLynx software (Waters) in centroid format. IF, CP and their urinary metabolites were identified through accurate mass measurement and the analysis of the MS/MS fragmentation patterns. Since IF and CP each have two chlorines, IF and CP metabolites could be identified and distinguished from endogenous metabolites based on the chlorine isotope ratio. For example, metabolites containing a single chlorine would be expected to exhibit a chlorine isotope ratio of 3:1. Metabolites containing two chlorines would be expected to have a chlorine isotope ratio of 9:6:1.

#### 2.4. *Data processing and multivariate data analysis (MDA)*

The mass chromatographic data were deconvoluted using MarkerLynx software (Waters), and a data matrix was generated for MDA. The ion intensity was calculated as the percentage of total ion counts (TIC) in the whole chromatogram. The data matrix was exported into SIMCA-P software (Umetrics, Kinnelon, NJ) for MDA. In order to separate drug metabolites

1 from endogenous metabolites in urine, the integrated ions in vehicle group and treatment  
2  
3 group were analyzed using an orthogonal projection to latent structures (OPLS) model. OPLS  
4  
5 analysis was conducted to represent the major latent variables in the data matrix and was  
6  
7 described in a scores scatter plot after data were Pareto scaled. Identification of IF, CP and  
8  
9 their metabolites was performed by analyzing the loadings plot and contribution table, as  
10  
11 previously described [34-39]. The general protocol for the identification of xenobiotic  
12  
13 metabolites using metabolomics has recently been reviewed [40].  
14  
15  
16  
17  
18  
19  
20

## 21 2.5. Tandem LC-MS quantitation of SCMC and TDGA

22  
23

24 Samples from IF- or CP-treated mice were prepared by mixing 20  $\mu$ l of urine with 80  $\mu$ l of  
25  
26 50% aqueous acetonitrile and centrifuging at  $18,000 \times g$  for 10 min. 10  $\mu$ l was injected for  
27  
28 LC-MS/MS analysis. LC-MS/MS analysis was performed on an Applied Biosystems API  
29  
30 2000 ESI triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA). A  
31  
32 Luna 3- $\mu$ m C18 50 mm  $\times$  46 mm internal diameter column (Phenomenex, Torrance, CA) was  
33  
34 used to separate SCMC, TDGA, and 4-nitrobenzoic acid (internal standard). The flow rate  
35  
36 was 0.2 ml/min with 95% aqueous acetonitrile containing 0.1% formic acid. The mass  
37  
38 spectrometer was operated in negative ion (ESI-) mode. The turbo ion spray temperature was  
39  
40 maintained at 350  $^{\circ}$ C, and a voltage of 5 kV was applied to the sprayer needle. Nitrogen was  
41  
42 used as the turbo ionspray and nebulizing gas. The detection and quantitation of SCMC,  
43  
44 TDGA and 4-nitrobenzoic acid (internal standard) were accomplished by multiple reaction  
45  
46 monitoring with the transitions  $m/z$  178.0/77.9 (SCMC), 149.0/92.7 (TDGA) and 165.9/109.6  
47  
48 (4-nitrobenzoic acid).  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 2.6. *Relative quantitation of the metabolites of IF and CP*

1  
2  
3  
4 Although the authentic standards of metabolites were unavailable, it was possible to  
5  
6  
7 determine their approximate abundance in the urine. Using several assumptions [38-39],  
8  
9  
10 including that the metabolites were equivalently eluted and ionized (ESI+) over the entire  
11  
12 chromatographic range, with equivalent degrees of ion suppression, it was possible to  
13  
14 approximate the relative excretion of IF, CP, and their metabolites in the urine. These  
15  
16 assumptions have been validated in a metabolomics study of the metabolism of ( $\pm$ )-arecoline  
17  
18 1-oxide in the mouse [39]. However, it is accepted that such estimates of relative  
19  
20  
21 concentration may be error-prone.  
22  
23  
24  
25  
26

## 2.7. *Statistical analysis*

27  
28  
29  
30  
31 Experimental values are expressed as mean  $\pm$  standard deviation (S.D.). Statistical  
32  
33 analysis was performed using independent Student's *t* tests or ANOVA. P-values less than  
34  
35  
36 0.05 were considered significant.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 3. Results

#### 3.1. *Metabolomic analysis of mouse urine after IF and CP administration*

After urine samples from the treated and control groups were analyzed by UPLC-ESI-QTOFMS, data were deconvoluted, and analyzed using OPLS. The advantage of OPLS is that the model is rotated so that class (treated and control) separation is found in the first predictive component,  $tp$ , also referred to as the correlated variation [41]. This multivariate model was built to determine the relationship between the treated and control groups, and the contribution of each detected urinary ion to the model. As shown in the scores scatter plot (Fig. 2A-B), urine samples from IF and CP treatment were clearly separated from the control in the first component ( $t[1]$ ), driven predominantly by the presence of drug and drug-related metabolites (Fig. 2C-D). The trend plots of ions from putative drug-related metabolites were used to display graphically the absence of those ions in vehicle-treated animals (Fig. 3A-E). The increased ions were further determined as drug-related or endogenous metabolites based on the mass defect shifts [42]. In general, the mass defects of phase I and II drug metabolites were over the range of -50 mDa and +50 mDa compared with the parent drug. After drug metabolites were determined, their chemical structures could be elucidated through MS/MS.

#### 3.2. *Identification and structural elucidation of the urinary metabolites of IF and CP*

After the metabolites were screened using OPLS and accurate mass measurement, their chemical structures were identified on the basis of the MS/MS fragmentation. Overall, IF (F1), CP (P1) and their 23 metabolites were identified in the urine samples from mice (Tables 2 and 3). Eighteen of them (F2, F3, F4, F6, F7, F8, F9, F10, F12, F13, P2, P3, P4, P5, P6, P7,

1 P8 and P10) are known metabolites, and five of them (F5, F11, P9, P11 and P12) were novel  
2  
3 metabolites. MS/MS spectra of the five novel metabolites (F5, F11, P9, P11 and P12) are  
4  
5 presented in Fig. 4.  
6  
7

8  
9 The empirical formula of F5 (iminoifosfamide), a new metabolite of IF, was calculated as  
10  
11  $C_7H_{13}Cl_2N_2O_2P$  (0.4 ppm mass error) based on the accurate mass measurement,  $m/z$   
12  
13 259.0171<sup>+</sup>. Compared with the chemical composition of IF ( $C_7H_{15}Cl_2N_2O_2P$ ), it was  
14  
15 concluded that F5 was a dehydrogenated form of IF. As seen from Fig. 4A, its molecular ion  
16  
17 peak showed three chlorine isotope peaks  $m/z$  259.012<sup>+</sup>, 261.012<sup>+</sup> and 263.138<sup>+</sup> with the ratio  
18  
19 of ion intensity 9:6:1, showing that F5 contained two chlorines. Tandem mass spectrometry  
20  
21 (MS/MS) revealed four major fragment ions at  $m/z$  230.986<sup>+</sup>, 182.013<sup>+</sup>, 153.982<sup>+</sup> (base peak),  
22  
23 118.042<sup>+</sup>. The fragment ion at  $m/z$  182.013<sup>+</sup> was generated by the cleavage of the *exo P-N*  
24  
25 bond to eliminate one chloroethylamine. The ion at  $m/z$  118.042<sup>+</sup> was formed by the  
26  
27 elimination of another chloroethyl group. It suggested that the double bond occurred in the  
28  
29 oxazaphosphorine ring. The parent ions produced the peak at  $m/z$  230.986<sup>+</sup> through the loss  
30  
31 of ethylene at the *C5-C6* bond of the oxazaphosphorine ring. The base peak at  $m/z$  153.982<sup>+</sup>  
32  
33 occurred from the ion at  $m/z$  182.013<sup>+</sup> by the same cleavage pattern. It was more stable for  
34  
35 the double bond between the *C4* and *C5* than that between the *C3* and *C4*, which was  
36  
37 consistent with the base peak. Therefore, F5 was identified as iminoifosfamide.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 F11 (4-hydroxyifosfamide glucuronide), a new metabolite of IF, was calculated as  
51  
52  $C_{13}H_{23}Cl_2N_2O_9P$  (2.6 ppm mass error) based on the accurate mass measurement,  $m/z$   
53  
54 453.0584<sup>+</sup>. As seen from Fig. 4B, its molecular ion peak showed three chlorine isotope peaks  
55  
56  $m/z$  453.056, 455.060<sup>+</sup> and 457.069<sup>+</sup> with the ratio of ion intensity 9:6:1, indicating that F11  
57  
58  
59  
60

1 contained two chlorines. It was clear that the base peak at  $m/z$  277.028<sup>+</sup> was produced from  
2  
3 its [M+H]<sup>+</sup> ion ( $m/z$  453.056<sup>+</sup>) by the loss of 176 Da. It was concluded that F11 was the  
4  
5 glucuronide conjugate of an hydroxylated metabolite of IF. MS/MS revealed major fragment  
6  
7 ions at  $m/z$  232.996<sup>+</sup>, 136.018<sup>+</sup>, and 92.023<sup>+</sup>. The fragment pattern was similar to the  
8  
9 metabolite 4-hydroxyifosfamide (F10). Therefore, F11 was identified as 4-hydroxyifosfamide  
10  
11 glucuronide.  
12  
13  
14  
15

16  
17 P9 (alcophosphamide glucuronide), a new metabolite of CP, was calculated as  
18  
19  $C_{13}H_{25}Cl_2N_2O_9P$  (2.6 ppm mass error) based on the accurate mass measurement,  $m/z$   
20  
21 455.0765<sup>+</sup>. As seen from Fig. 4E, its molecular ion showed three chlorine isotope peaks  $m/z$   
22  
23 455.074<sup>+</sup>, 457.076<sup>+</sup> and 459.069<sup>+</sup> with the ratio of ion intensity 9:6:1, demonstrating that P9  
24  
25 contained two chlorines. In its MS/MS spectrum, the base peak at  $m/z$  279.043<sup>+</sup> was  
26  
27 generated from its [M+H]<sup>+</sup> ion ( $m/z$  455.074<sup>+</sup>) by the elimination of 176 Da. It was concluded  
28  
29 that P9 was the glucuronide conjugate. MS/MS revealed its major fragments at  $m/z$  262.017<sup>+</sup>,  
30  
31 221.000<sup>+</sup>, and 138.032<sup>+</sup>, which was similar to fragments of the metabolite alcophosphamide  
32  
33 (P5). Therefore, P9 was identified as alcophosphamide glucuronide.  
34  
35  
36  
37  
38  
39  
40  
41

42 P11 (dechloroethylketocyclophosphamide), a novel metabolite of CP, was calculated as  
43  
44  $C_5H_{10}ClN_2O_3P$  (0.9 ppm mass error) based on the accurate mass measurement,  $m/z$   
45  
46 213.0198<sup>+</sup>. Compared with the [M+H]<sup>+</sup> ion ( $m/z$  275.010<sup>+</sup>) of 4-ketocyclophosphamide, P11  
47  
48 was lower by 62 Da than 4-ketocyclophosphamide. *N*-dechloroethylation was the common  
49  
50 pattern in the metabolism of CP through the loss of 62 Da. It was concluded, therefore, that  
51  
52 P11 was generated from alcophosphamide through the elimination of the chloroethyl group.  
53  
54  
55  
56  
57  
58 As seen from Fig. 4C, its molecular ion peak showed two chlorine isotope peaks  $m/z$   
59  
60

1 213.019<sup>+</sup> and 215.025<sup>+</sup> with the ratio of ion intensity 3:1, showing that P11 contained one  
2  
3 chlorine. MS/MS revealed its major fragments at  $m/z$  159.011<sup>+</sup>, 141.983<sup>+</sup> and 112.077<sup>+</sup>,  
4  
5  
6 which was similar to the major fragments of 4-ketocyclophosphamide. Therefore, P11 was  
7  
8 identified as dechloroethylketocyclophosphamide.  
9

10  
11 P12 (dechloroethylalcohosphamide), a novel metabolite of CP, was calculated as  
12  
13  $C_5H_{14}ClN_2O_3P$  (0.9 ppm mass error) based on the accurate mass measurement,  $m/z$   
14  
15 217.0511<sup>+</sup>. The  $[M+H]^+$  ion of P12 was lower by 62 Da than that of alcophosphamide ( $m/z$   
16  
17 279.0437<sup>+</sup>). Compared with the metabolite P11, P12 was supposed to be the *N*-  
18  
19 dechloroethylated product of alcophosphamide. As seen in Fig. 4D, its molecular ion showed  
20  
21 two chlorine isotope peaks,  $m/z$  217.052<sup>+</sup> and 219.054<sup>+</sup> with the ratio of ion intensity 3:1,  
22  
23 demonstrating that P12 contained only one chlorine. MS/MS revealed its major fragments at  
24  
25  $m/z$  200.022<sup>+</sup>, 159.008<sup>+</sup>, and 138.031<sup>+</sup>. The base peaks at  $m/z$  159.008<sup>+</sup> was produced by the  
26  
27 cleavage of the -CH<sub>2</sub>CH<sub>2</sub>OH group at the C-O bond. The fragment at  $m/z$  200.022<sup>+</sup> was  
28  
29 generated from the loss of the hydroxyl group. The fragment at  $m/z$  138.031<sup>+</sup> was produced  
30  
31 from the hydroxylation and chloroethylation of P12. The cleavage pattern was similar to the  
32  
33 alcophosphamide. Therefore, P12 was identified as dechloroethylalcohosphamide.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

### 44 3.3. Estimation of relative concentrations of IF and CP metabolites by chromatographic 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65

66  
67 Based on their exact masses, peaks were extracted from the UPLC chromatograms, and  
68  
69 areas integrated (Tables 2 and 3). The metabolites of IF and CP were grouped by metabolic  
70  
71 transformation, as follows: dechloroethylation, hydroxylation, ketonization, dehydroxylation,  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100

1 alkylation, ring-opening, and conjugation reactions (Table 4). As shown in Fig. 5, the  
2  
3 excretion of the unchanged IF in mouse urine was similar to the excretion of CP. The  
4  
5  
6 dechloroethylated metabolites of IF were present in higher concentrations than CP (2-fold).  
7  
8  
9 The ring-opened and ketonization metabolites of CP were present at higher concentrations  
10  
11 than IF (5-fold and 3-fold, respectively). In addition, although the hydroxylated,  
12  
13 dehydroxylated, alkylated, and conjugated metabolites were different between IF and CP,  
14  
15 their relative abundance in the urine was very low following treatment with either IF or CP.  
16  
17  
18  
19  
20

### 21 3.4. Urinary excretion of SCMC and TDGA

22  
23

24 After the treatment of mice with either IF or CP, SCMC (F12) and TDGA (F13) excretion  
25  
26 was increased above endogenous levels. Because of their low molecular weight and weak  
27  
28 acidity, SCMC and TDGA could be detected in negative ion mode of using UPLC-ESI-  
29  
30 QTOF-MS. However, their concentration was determined by triple quadrupole mass  
31  
32 spectrometry. From Fig. 6A, it can be seen that SCMC excretion was increased 32-fold and  
33  
34 44-fold in urine above endogenous levels, respectively, after treatment with IF and CP.  
35  
36 TDGA excretion was also increased in urine by 14-fold and 17-fold following IF and CP  
37  
38 treatment, respectively. Therefore, both isomeric drugs show surprisingly similar profiles  
39  
40  
41 with respect to these metabolites.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



#### 4. Discussion

Metabolomics is an invaluable tool for profiling biological fluids for small molecules, and with respect to pharmacology, metabolomics has provided substantial insight into drug metabolism pathways. For example, the metabolic map of acetaminophen (which had been studied for over 40 years) was recently expanded by three metabolites [37]. Similarly, the metabolic maps of IF and CP were expanded (two IF and three CP new metabolites) and 18 known metabolites that otherwise had taken over 40 years to identify (Table 1) are also reported here. This demonstrates the power of UPLC-ESI-QTOFMS-based metabolomics applied to the study of drug metabolism.

IF and CP are prodrugs that are converted to their active forms during metabolic biotransformation [43]. Their biological activity is mediated through their active metabolites, including 4-hydroxyifosfamide and 4-hydroxycyclophosphamide, both of which were detected in this study. Because of their respective equilibrium with aldoifosfamide and aldophosphamide, a minor amount of 4-hydroxyifosfamide and 4-hydroxycyclophosphamide were excreted in the urine. Aldoifosfamide was both reduced and oxidized to alcoifosfamide and carboxyifosfamide, respectively, presumably by the action of alcohol dehydrogenase and aldehyde dehydrogenase [26]. In a similar manner, aldophosphamide was both reduced and oxidized to alcophosphamide and carboxyphosphamide, respectively [44]. It can be seen from Fig. 5 that ring-opened metabolites were produced to a greater extent from CP than from IF, and this was the major difference between the two drugs. However, in compensation, the dechloroethylated metabolites of IF were excreted to a greater extent than from CP. SCMC and TDGA, both normal products of endogenous metabolism, were found at

1 low concentrations in control urine. Following treatment with IF and CP, SCMC and TDGA  
2  
3 were significantly elevated *in vivo* (Fig. 6). It is known that CAA can lead to the formation of  
4  
5 SCMC through conjugation with cysteine or glutathione, and SCMC is further transformed to  
6  
7 TDGA [45]. SCMC has been reported to activate the  $\alpha$ -amino-3-hydroxy-5-methyl-4-  
8  
9 isoxazolepropionic acid (AMPA)/kainite receptor and induce cellular acidification which  
10  
11 may be responsible for the reported encephalopathy [46-47]. In addition, TDGA can cause  
12  
13 mitochondrial dysfunction which may also contribute to the side-effects associated with IF  
14  
15 treatment [48]. However, there have been no reports that SCMC and TDGA resulting from  
16  
17 the treatment by CP lead to toxicity. Here, SCMC and TDGA were detected in urine from the  
18  
19 CP-treated mice. The generation of CAA from IF was greater than from CP, according to the  
20  
21 significantly higher rate of *N*-dechloroethylation of IF (Fig. 5) Surprisingly therefore, there  
22  
23 were no significant differences in SCMC and TDGA production in IF- and CP-treated mice  
24  
25 (Fig. 6B and D). However, it was previously reported that TDGA is the major urinary  
26  
27 metabolite in cancer patients treated with IF and this was suggested as the causative IF  
28  
29 metabolite of encephalopathy [48]. Apparently, TDGA is an inconsequential urinary  
30  
31 metabolite of CP (A. Küpfer, unpublished observation). However, TDGA was determined in  
32  
33 these human studies by lyophilization and derivatization of urines with BF<sub>3</sub>/methanol at 60  
34  
35 °C, in contrast to the studies described here where diluted urines were injected directly into  
36  
37 the tandem mass spectrometer. It is therefore possible that TDGA is formed during the  
38  
39 heating process, either by spontaneous decarboxylation of the  $\alpha$ -keto acid of SCMC (*S*-  
40  
41 carboxymethyl-3-thiopyruvic acid; SCMTPA) [46-47] or from an acid- or heat-labile ester,  
42  
43 such as the carnitine ester of TDGA.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Previous studies suggested that IF treatment resulted in changes in the excretion patterns  
2  
3 of low molecular weight endogenous metabolites (hippuric acid, trimethylamine *N*-oxide,  
4  
5 glycine, lactate, histidine and glucose), which were regarded as biomarkers of IF  
6  
7 nephrotoxicity and encephalopathy [49]. The current findings suggest that IF-induced side-  
8  
9 effects may result directly from CAA rather than from SCMC and TDGA. Studies have  
10  
11 reported that CAA can result in neurotoxicity and nephrotoxicity [50-51]. This observation  
12  
13 may offer one potential mechanism to explain IF-related neurotoxicity and nephrotoxicity.  
14  
15  
16  
17  
18  
19

20 Despite the large number of published *in vitro* and *in vivo* CP and IFO metabolism  
21  
22 studies, five novel metabolites (F5, F11, P9, P11 and P12) were found by metabolomic  
23  
24 analysis in this study. Iminoifosfamide from IF corresponded to iminocyclophosphamide (F6)  
25  
26 from CP. Previous studies reported some conjugated metabolites with GSH from IF and CP,  
27  
28 such as ifosforamide mustard and cyclophosphamide [14, 52]. However, there was no GSH  
29  
30 conjugation detected in either urine and serum. Here, two minor glucuronide conjugate  
31  
32 metabolites (F11 and P9) were found from IF- and CP-treated mice. Furthermore, two new *N*-  
33  
34 dechloroethylated (P11 and P12) metabolites from CP were found in the urine (Fig. 8).  
35  
36 Inspection of the loadings S-plot in Fig. 2D suggests that P11 has a similar abundance to the  
37  
38 principal *N*-dechloroethylated metabolite P3, while P12 is a much more minor metabolite.  
39  
40  
41  
42  
43  
44  
45  
46

47 The metabolomic studies described here were carried out in the mouse. As shown in Table  
48  
49 1, rat and human have been the principal species studied historically for CP and IF  
50  
51 metabolism. There are relatively few data in the mouse. Nevertheless, the value of the mouse  
52  
53 is that future studies may be conducted in genetically modified mice, that permit direct  
54  
55 questions to be asked about the role of discrete enzymes and the nuclear receptors that control  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 their expression in the liver and other tissues [33]. It may be envisaged that data from mice  
2  
3 humanized for CP and IF metabolizing enzyme genes could be compared with actual clinical  
4  
5 data for these drugs, thus refining and improving animal modeling of cancer chemotherapy.  
6  
7

8  
9 In conclusion, the present study investigated IF and CP in mice using a metabolomic  
10  
11 approach, which gave a comprehensive understanding of their metabolism *in vivo*. Twenty  
12  
13 three urinary metabolites, including five novel drug metabolites, were identified and  
14  
15 structurally elucidated by mass fragmentography. Their metabolic pathways *in vivo* were  
16  
17 presented. Although they went through similar metabolic processes, the amount of  
18  
19 metabolites in urine was significantly different between IF and CP, in particular, the *N*-  
20  
21 dechloroethylated and ring-opened metabolites. SCMC and TDGA, that have been regarded  
22  
23 as the toxic metabolites, specifically of IF [46-48], were also found in similar amounts in the  
24  
25 urine of IF- and CP-treated mice. Future studies are needed to examine the potential of CAA,  
26  
27 SCMTPA or TDGA carnitine ester to be the causative factors in IF-associated neuro- and  
28  
29 nephrotoxicity.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Acknowledgements**

This work was supported in part by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health. JRI is grateful to the U.S. Smokeless Tobacco Company for a grant for collaborative research. The authors thank Professor Adrian Küpfer, University of Bern, for helpful discussions.

Accepted Manuscript

## References

- 1  
2  
3 [1] Druckrey H, Raabe S. Specific chemotherapy of carcinoma of the prostate. *Klin*  
4  
5  
6 *Wochenschr* 1952;30:882-4.  
7  
8  
9 [2] Arnold H, Bourseaux F, Brock N. Chemotherapeutic action of a cyclic nitrogen  
10  
11 mustard phosphamide ester (B 518-ASTA) in experimental tumours of the rat. *Nature*  
12  
13  
14 1958;181:931.  
15  
16  
17 [3] Brock N, Hohorst HJ. Metabolism of cyclophosphamide. *Cancer* 1967;20:900-4.  
18  
19  
20 [4] Sladek NE. Evidence for an aldehyde possessing alkylating activity as the primary  
21  
22 metabolite of cyclophosphamide. *Cancer Res* 1973;33:651-8.  
23  
24  
25 [5] Hill DL, Laster WR, Jr., Struck RF. Enzymatic metabolism of cyclophosphamide and  
26  
27  
28 nicotine and production of a toxic cyclophosphamide metabolite. *Cancer Res*  
29  
30  
31 1972;32:658-65.  
32  
33  
34 [6] Alarcon RA, Meienhofer J. Formation of the cytotoxic aldehyde acrolein during *In*  
35  
36 *vitro* degradation of cyclophosphamide. *Nature New Biol* 1971;233:250-2.  
37  
38  
39 [7] Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M. Some studies of the active  
40  
41  
42 intermediates formed in the microsomal metabolism of cyclophosphamide and  
43  
44  
45 isophosphamide. *Biochem Pharmacol* 1974;23:115-29.  
46  
47  
48 [8] Colvin M, Padgett CA, Fenselau C. A biologically active metabolite of  
49  
50  
51 cyclophosphamide. *Cancer Res* 1973;33:915-8.  
52  
53  
54 [9] Struck RF, Kirk MC, Mellett LB, el Dareer S, Hill DL. Urinary metabolites of the  
55  
56  
57 antitumor agent cyclophosphamide. *Mol Pharmacol* 1971;7:519-29.  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [10] Fenselau C, Lehman JP, Myles A, Brandt J, Yost GS, Friedman OM, et al.  
2  
3 Iminocyclophosphamide as a chemically reactive metabolite of cyclophosphamide.  
4  
5  
6 Drug Metab Dispos 1982;10:636-40.  
7  
8
- 9 [11] Struck RF, Kirk MC, Witt MH, Laster WR, Jr. Isolation and mass spectral  
10  
11 identification of blood metabolites of cyclophosphamide: evidence for phosphoramidate  
12  
13 mustard as the biologically active metabolite. Biomed Mass Spectrom 1975;2:46-52.  
14  
15  
16
- 17 [12] Brock N. New nitrogen mustard phosphamide esters and their cytostatic activity.  
18  
19  
20 Laval Med 1968;39:696-701.  
21  
22
- 23 [13] Alarcon RA, Meienhofer J, Atherton E. Isophosphamide as a new acrolein-producing  
24  
25 antineoplastic isomer of cyclophosphamide. Cancer Res 1972;32:2519-23.  
26  
27
- 28 [14] Dirven HA, Megens L, Oudshoorn MJ, Dingemans MA, van Ommen B, van  
29  
30 Bladeren PJ. Glutathione conjugation of the cytostatic drug ifosfamide and the role of  
31  
32 human glutathione S-transferases. Chem Res Toxicol 1995;8:979-86.  
33  
34  
35
- 36 [15] Norpoth K. Studies on the metabolism of isophosphamide (NSC-109724) in man.  
37  
38  
39 Cancer Treat Rep 1976;60:437-43.  
40  
41
- 42 [16] Goren MP, Wright RK, Pratt CB, Pell FE. Dechloroethylation of ifosfamide and  
43  
44 neurotoxicity. Lancet 1986;2:1219-20.  
45  
46
- 47 [17] Highley MS, Momerency G, Van Cauwenberghe K, Van Oosterom AT, de Bruijn  
48  
49  
50 EA, Maes RA, et al. Formation of chloroethylamine and 1,3-oxazolidine-2-one  
51  
52 following ifosfamide administration in humans. Drug Metab Dispos 1995;23:433-7.  
53  
54
- 55 [18] Norpoth K, Raidt H, Witting U, Muller G, Norpoth R. Side chain oxidation of  
56  
57  
58 ifosfamide in man. Klin Wochenschr 1975;53:1075-6.  
59  
60

- 1 [19] Shaw IC, Graham MI, McLean AE. 2-Chloroacetaldehyde: a metabolite of  
2  
3 cyclophosphamide in the rat. *Cancer Treat Rev* 1983;10 Suppl A:17-24.  
4  
5
- 6 [20] Shaw IC, Graham MI, McLean AE. 2-Chloroacetaldehyde, a metabolite of  
7  
8 cyclophosphamide in the rat. *Xenobiotica* 1983;13:433-7.  
9  
10
- 11 [21] Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR. Pharmacokinetics and  
12  
13 metabolism of ifosfamide administered as a continuous infusion in children. *Cancer*  
14  
15 *Res* 1993;53:3758-64.  
16  
17
- 18 [22] Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR. Comparison of  
19  
20 continuous infusion and bolus administration of ifosfamide in children. *Eur J Cancer*  
21  
22 1995;31A:785-90.  
23  
24  
25
- 26 [23] Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR. Intrasubject variation  
27  
28 in children of ifosfamide pharmacokinetics and metabolism during repeated  
29  
30 administration. *Cancer Chemother Pharmacol* 1996;38:147-54.  
31  
32  
33
- 34 [24] Boddy AV, Cole M, Pearson AD, Idle JR. The kinetics of the auto-induction of  
35  
36 ifosfamide metabolism during continuous infusion. *Cancer Chemother Pharmacol*  
37  
38 1995;36:53-60.  
39  
40  
41
- 42 [25] Boddy AV, Proctor M, Simmonds D, Lind MJ, Idle JR. Pharmacokinetics,  
43  
44 metabolism and clinical effect of ifosfamide in breast cancer patients. *Eur J Cancer*  
45  
46 1995;31A:69-76.  
47  
48  
49
- 50 [26] Martino R, Crasnier F, Chouini-Lalanne N, Gilard V, Niemyer U, De Forni M, et al.  
51  
52 A new approach to the study of ifosfamide metabolism by the analysis of human body  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



- 1 fluids with <sup>31</sup>P nuclear magnetic resonance spectroscopy. *J Pharmacol Exp Ther*  
2  
3 1992;260:1133-44.  
4  
5  
6 [27] Brock N, Pohl J, Stekar J. Detoxification of urotoxic oxazaphosphorines by sulfhydryl  
7  
8 compounds. *J Cancer Res Clin Oncol* 1981;100:311-20.  
9  
10  
11 [28] Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G. Acrolein, the causative factor of  
12  
13 urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.  
14  
15 *Arzneimittelforschung* 1979;29:659-61.  
16  
17  
18 [29] Aeschlimann C, Cerny T, Kupfer A. Inhibition of (mono)amine oxidase activity and  
19  
20 prevention of ifosfamide encephalopathy by methylene blue. *Drug Metab Dispos*  
21  
22 1996;24:1336-9.  
23  
24  
25  
26 [30] Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms  
27  
28 of ifosfamide encephalopathy. *Eur J Clin Pharmacol* 1996;50:249-52.  
29  
30  
31  
32 [31] Dubourg L, Michoudet C, Cochat P, Baverel G. Human kidney tubules detoxify  
33  
34 chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. *J Am Soc*  
35  
36 *Nephrol* 2001;12:1615-23.  
37  
38  
39  
40 [32] Loqueviel C, Malet-Martino M, Martino R. A <sup>13</sup>C NMR study of 2-(<sup>13</sup>C)-  
41  
42 chloroacetaldehyde, a metabolite of ifosfamide and cyclophosphamide, in the isolated  
43  
44 perfused rabbit heart model. Initial observations on its cardiotoxicity and cardiac  
45  
46 metabolism. *Cell Mol Biol (Noisy-le-grand)* 1997;43:773-82.  
47  
48  
49  
50 [33] Cheung C, Gonzalez FJ. Humanized mouse lines and their application for prediction  
51  
52 of human drug metabolism and toxicological risk assessment. *J Pharmacol Exp Ther*  
53  
54 2008;327:288-99.  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [34] Chen C, Ma X, Malfatti MA, Krausz KW, Kimura S, Felton JS, et al. A  
2 comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine  
3 (PhIP) metabolism in the mouse using a multivariate data analysis approach. *Chem*  
4  
5  
6 (PhIP) metabolism in the mouse using a multivariate data analysis approach. *Chem*  
7  
8  
9 *Res Toxicol* 2007;20:531-42.
- 10  
11 [35] Ma X, Chen C, Krausz KW, Idle JR, Gonzalez FJ. A metabolomic perspective of  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [36] Chen C, Meng L, Ma X, Krausz KW, Pommier Y, Idle JR, et al. Urinary metabolite  
profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). *J*  
*Pharmacol Exp Ther* 2006;318:1330-42.
- [37] Chen C, Krausz KW, Idle JR, Gonzalez FJ. Identification of novel toxicity-associated  
metabolites by metabolomics and mass isotopomer analysis of acetaminophen  
metabolism in wild-type and Cyp2e1-null mice. *J Biol Chem* 2008;283:4543-59.
- [38] Giri S, Idle JR, Chen C, Zabriskie TM, Krausz KW, Gonzalez FJ. A metabolomic  
approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the  
mouse. *Chem Res Toxicol* 2006;19:818-27.
- [39] Giri S, Krausz KW, Idle JR, Gonzalez FJ. The metabolomics of (+/-)-arecoline 1-  
oxide in the mouse and its formation by human flavin-containing monooxygenases.  
*Biochem Pharmacol* 2007;73:561-73.
- [40] Patterson AD, Gonzalez FJ, Idle JR. Xenobiotic metabolism: A view through the  
metabolometer. *Chem Res Toxicol* 2010;doi: 10.1021/tx100020p.
- [41] Wiklund S, Johansson E, Sjoström L, Mellerowicz EJ, Edlund U, Shockcor JP, et al.  
Visualization of GC/TOF-MS-based metabolomics data for identification of

- 1 biochemically interesting compounds using OPLS class models. *Anal Chem*  
2  
3 2008;80:115-22.  
4  
5  
6 [42] Zhang H, Zhang D, Ray K, Zhu M. Mass defect filter technique and its applications to  
7  
8 drug metabolite identification by high-resolution mass spectrometry. *J Mass Spectrom*  
9 2009;44:999-1016.  
10  
11  
12 [43] Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, et al. Metabolism and  
13  
14 transport of oxazaphosphorines and the clinical implications. *Drug Metab Rev*  
15 2005;37:611-703.  
16  
17  
18 [44] Joqueviel C, Martino R, Gilard V, Malet-Martino M, Canal P, Niemeyer U. Urinary  
19  
20 excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear  
21  
22 magnetic resonance spectroscopy. *Drug Metab Dispos* 1998;26:418-28.  
23  
24  
25 [45] Steventon GB. Diurnal variation in the metabolism of S-carboxymethyl-L-cysteine in  
26  
27 humans. *Drug Metab Dispos* 1999;27:1092-7.  
28  
29  
30 [46] Chatton JY, Idle JR, Vagbo CB, Magistretti PJ. Insights into the mechanisms of  
31  
32 ifosfamide encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-  
33  
34 hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors and induce  
35  
36 cellular acidification in mouse cortical neurons. *J Pharmacol Exp Ther*  
37 2001;299:1161-8.  
38  
39  
40 [47] Lerch S, Kupfer A, Idle JR, Lauterburg BH. Cerebral formation in situ of S-  
41  
42 carboxymethylcysteine after ifosfamide administration to mice: a further clue to the  
43  
44 mechanism of ifosfamide encephalopathy. *Toxicol Lett* 2006;161:188-94.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [48] Visarius TM, Bahler H, Kupfer A, Cerny T, Lauterburg BH. Thiodiglycolic acid is  
2 excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats.  
3  
4 Drug Metab Dispos 1998;26:193-6.  
5  
6  
7  
8  
9 [49] Foxall PJ, Singer JM, Hartley JM, Neild GH, Lapsley M, Nicholson JK, et al. Urinary  
10 proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and  
11 encephalopathy. Clin Cancer Res 1997;3:1507-18.  
12  
13  
14  
15  
16  
17 [50] Springate JE. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in  
18 vivo. J Appl Toxicol 1997;17:75-9.  
19  
20  
21  
22 [51] Woodland C, Ito S, Granvil CP, Wainer IW, Klein J, Koren G. Evidence of renal  
23 metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 2000;68:109-17.  
24  
25  
26  
27  
28 [52] Dirven HA, van Ommen B, van Bladeren PJ. Involvement of human glutathione S-  
29 transferase isoenzymes in the conjugation of cyclophosphamide metabolites with  
30 glutathione. Cancer Res 1994;54:6215-20.  
31  
32  
33  
34  
35  
36 [53] Rauen HM, Norpoth K. High tension electrophoretic studies on metabolites of N,N-  
37 bis(2-chlorethyl)-N',O-propylenephosphoric acid ester-diamide from the serum of  
38 rats. Arzneimittelforschung 1967;17:599-602.  
39  
40  
41  
42  
43  
44 [54] Norpoth K, Addicks HW, Witting U, Muller G, Raidt H. Quantitative determination  
45 of cyclophosphamide, ifosfamide, and trofosfamide and their stable metabolites on  
46 TLC-plates with the aid of 4-pyridine-aldehyde-2-benzothiazolyl-hydrazone (PBH)  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56 [55] Cox PJ, Levin L. Novel metabolic products of cyclophosphamide in human urine.  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [56] Alarcon RA. Studies on the in vivo formation of acrolein: 3-hydroxy-  
2  
3 propylmercapturic acid as an index of cyclophosphamide (NSC-26271) activation.  
4  
5  
6 Cancer Treat Rep 1976;60:327-35.  
7  
8
- 9 [57] Voelcker G, Wagner T, Hohorst HJ. Identification and pharmacokinetics of  
10  
11 cyclophosphamide (NSC-26271) metabolites in vivo. Cancer Treat Rep 1976;60:415-  
12  
13  
14 22.  
15  
16
- 17 [58] Jardine I, Fenselau C, Appler M, Kan MN, Brundrett RB, Colvin M. Quantitation by  
18  
19 gas chromatography-chemical ionization mass spectrometry of cyclophosphamide,  
20  
21 phosphoramidate mustard, and nor-nitrogen mustard in the plasma and urine of patients  
22  
23 receiving cyclophosphamide therapy. Cancer Res 1978;38:408-15.  
24  
25  
26
- 27 [59] Chan KK, Hong SC, Watson E, Deng SK. Identification of new metabolites of  
28  
29 phosphoramidate and nor-nitrogen mustards and cyclophosphamide in rat urine using  
30  
31 ion cluster techniques. Biomed Environ Mass Spectrom 1986;13:145-54.  
32  
33  
34
- 35 [60] Hadidi AH, Coulter CE, Idle JR. Phenotypically deficient urinary elimination of  
36  
37 carboxyphosphamide after cyclophosphamide administration to cancer patients.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [61] Hadidi AH, Idle JR. Combined thin-layer chromatography-photography-densitometry  
for the quantitation of cyclophosphamide and its four principal urinary metabolites. J  
Chromatogr 1988;427:121-30.
- [62] Boddy AV, Idle JR. Combined thin-layer chromatography-photography-densitometry  
for the quantification of ifosfamide and its principal metabolites in urine,  
cerebrospinal fluid and plasma. J Chromatogr 1992;575:137-42.

- 1 [63] Fraiser L, Kehrer JP. Murine strain differences in metabolism and bladder toxicity of  
2 cyclophosphamide. *Toxicology* 1992;75:257-72.  
3  
4  
5  
6 [64] Wang JJ, Chan KK. Analysis of ifosfamide, 4-hydroxyifosfamide, N2-  
7  
8 dechloroethylifosfamide, N3-dechloroethylifosfamide and iphosphoramidate mustard in  
9  
10 plasma by gas chromatography-mass spectrometry. *J Chromatogr B Biomed Appl*  
11  
12 1995;674:205-17.  
13  
14  
15  
16 [65] Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, et al. Cyclophosphamide  
17  
18 metabolism in children. *Cancer Res* 1995;55:803-9.  
19  
20  
21  
22 [66] Linhart I, Frantik E, Vodickova L, Vosmanska M, Smejkal J, Mitera J.  
23  
24 Biotransformation of acrolein in rat: excretion of mercapturic acids after inhalation  
25  
26 and intraperitoneal injection. *Toxicol Appl Pharmacol* 1996;136:155-60.  
27  
28  
29  
30 [67] Aeschlimann C, Kupfer A, Schefer H, Cerny T. Comparative pharmacokinetics of  
31  
32 oral and intravenous ifosfamide/mesna/methylene blue therapy. *Drug Metab Dispos*  
33  
34 1998;26:883-90.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 **Figure Legends:**

2  
3  
4 **Fig. 1.** Metabolic activation and transport of IF and CP *in vivo*. (A) Rational design of CP  
5 based upon its supposed metabolism in tumor tissue *versus* a contemporary view of CP  
6  
7 metabolism. (B) A contemporary view of IF metabolism, including the *N*-dechloroethylation  
8  
9 reactions that lead to two-carbon metabolites and ultimately SCMS and TDGA.  
10  
11  
12  
13

14  
15  
16 **Fig. 2.** Identification of urinary IF and CP metabolites through LC-MS-based metabolomics.

17  
18 (A) Scores plot of an OPLS model from control and IF-treated mice. Each point represents an  
19 individual mouse urine (B) Scores plot of a OPLS model from control and CP-treated mice.  
20  
21 Each point represents an individual mouse urine (C) OPLS loadings S-plot of urinary ions  
22  
23 from control and IF-treated mice. Each point represents a urinary ion (D) OPLS loadings S-  
24  
25 plot of chemical ions from control and CP-treated mice. Each point represents a urinary ion.  
26  
27  
28  
29  
30

31  
32  
33 **Fig. 3.** Trend plots of ions from novel metabolites in the treatment groups. (A) Novel IF  
34 metabolites with *m/z* values of 259.0171 (F5) and 453.0584 (F11). (B) Novel CP metabolites  
35  
36 with *m/z* values 213.0198 (P11), 217.0511 (P12), and 455.0781 (P9). Note the absence of  
37  
38 suspected drug metabolites in the vehicle-treated group. Metabolite codes correspond to those  
39  
40  
41  
42  
43  
44  
45 in Fig. 4.

46  
47  
48 **Fig. 4.** Tandem MS and chemical structures of novel CP and IF metabolites. (A)  
49 Iminoifosfamide (F5). (B) 4-Hydroxyifosfamide glucuronide (F11). (C)  
50  
51 Dechloroethylketocyclophosphamide (P11). (D) Dechloroethylalcophosphamide (P12). (E)  
52  
53 Alcophosphamide glucuronide (P9). Note the chlorine isotope ratios depending on the  
54  
55 presence of a one (3:1 ratio) or two (9:6:1) chlorine atoms.  
56  
57  
58  
59  
60

1 **Fig. 5.** Relative quantitation of urinary metabolites from different groups of metabolic  
2 pathways in mouse urine following the treatment of IF and CP. Except for unchanged IF and  
3 CP, there were significant differences in these metabolites with similar chemical structures  
4 from IF and CP. NS, not significant. Note that the  $\beta$ -elimination of acrolein (IF>CP;  $P<0.05$ )  
5 and glucuronidation (CP>IF;  $P<0.01$ ) pathways were very minor compared to other  
6 pathways, but nevertheless showed statistically significant differences.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

18 **Fig. 6.** The amount ( $\mu\text{mol}/24\text{h}$ ) and % dose excreted for SCMC and TDGA in 0-24 h mouse  
19 urines following treatment with IF and CP. (A) The  $\mu\text{mol}/24\text{h}$  of SCMC from IF- and CP-  
20 treated mice. (B) Percent dose excretion of SCMC from IF- and CP-treated mice. (C) The  
21  $\mu\text{mol}/24\text{h}$  of TDGA from IF- and CP-treated mice. (D) Percent dose excretion of TDGA from  
22 IF- and CP-treated mice. N.S. means not significant. Note the small amounts of SCMC and  
23 TDGA excreted in blank (control) 0-24 h mouse urines.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 **Fig. 7.** Major *in vivo* IF metabolic pathways showing the enzyme systems that are believed to  
36 produce each metabolite. Boxed structures represent novel metabolites.  
37  
38  
39  
40  
41

42 **Fig. 8.** Major *in vivo* CP metabolic pathways showing the enzyme systems that are believed  
43 to produce each metabolite. Boxed structures represent novel metabolites.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



**Table 1** Reported metabolites of IF and CP *in vivo* and *in vitro*.

Year	Drug	Metabolite	Species	Reference
1967	CP	Nornitrogen mustard 2-Chloroethylaziridine (decomposition products of unknown primary metabolite)	Rat (iv)	[3]
1967	CP	Hydracrylic acid	PB-induced rats (ip)	[53]
1971	CP	Carboxycyclophosphamide 4-Oxocyclophosphamide	Dog (iv), Human (iv)	[9]
1971	CP	Acrolein	Liver microsomes	[9]
1972	IF	Acrolein	PB-induced rat liver microsomes	[13]
1972	CP	Aldophosphamide	Uninduced mouse liver microsomes	[5]
1973	CP	4-Hydroxycyclophosphamide [tautomer of aldophosphamide]	PB-induced rat liver microsomes	[4]
1973	CP	Phosphoramidate mustard	PB-induced mouse liver microsomes	[8]
1974	IF	2-Dechloroethylifosfamide 3-Dechloroethylifosfamide 4-Hydroxyifosfamide	PB-induced rat liver microsomes	[7]
1975	IF	2-Chloroethylamine	Rat (iv), Human (iv)	[54]
1975	CP	3-(2-Chloroethyl)oxazolidone (from nornitrogen mustard + CO <sub>2</sub> )	Human (iv)	[55]
1975	CP	4-Oxocyclophosphamide Alcophosphamide 2-Dechloroethylcyclophosphamide Carboxyphosphamide Phosphoramidate mustard Nornitrogen mustard	Mice (ip)	[11]
1976	CP IF	3-Hydroxypropylmercapturic acid [metabolite of acrolein]	Rat	[56]
1976	IF	Carboxyifosfamide (1.4%) 2-Dechloroethylifosfamide (6.2%) 3-Dechloroethylifosfamide (12.5%) S-Carboxymethylcysteine (10.4%) Thiodiglycolic acid (4.7%)	Human (iv)	[15]
1976	CP	4-Hydroxycyclophosphamide Aldophosphamide Phosphoramidate mustard 4-Oxocyclophosphamide	Rat (ip), Mouse (ip)	[57]
1978	CP	Phosphoramidate mustard Nornitrogen mustard (?artifact)	Human (iv)	[58]
1982	CP	Iminocyclophosphamide	Immobilized rabbit liver P450	[10]
1983	CP	2-Chloroacetaldehyde	Rat (iv)	[20]
1986	CP	3-(2-chloroethyl)-1,3-oxazolidin-2-one 3-(2-chloroethyl)-4-hydroxy-1,3-oxazolidin-2-one 3-(2-hydroxyethyl)-1,3-oxazolidin-2-one	Rat (iv)	[59]
1986	IF	2-Chloroacetaldehyde	Human (iv)	[16]
1988	CP	4-Oxocyclophosphamide Carboxyphosphamide	Human (iv)	[60-61]

## Phosphoramidate mustard

**Table 1** (Continued)

Year	Drug	Metabolite	Species	Reference
1992	CP	Dechloroethylcyclophosphamide 4-Oxocyclophosphamide Carboxyphosphamide Phosphoramidate mustard	Human (iv)	[62]
1992	CP	Acrolein [dose- and strain-dependency]	ICR mouse (ip) C57BL/6N mouse (ip)	[63]
1992	IF	Isophosphoramidate mustard Carboxyifosfamide 2-Dechloroethylifosfamide 3-Dechloroethylifosfamide 4-Oxoifosfamide	Human (iv)	[26]
1993	IF	Isophosphoramidate mustard Carboxyifosfamide 2-Dechloroethylifosfamide 3-Dechloroethylifosfamide 4-Oxoifosfamide	Human [children] (iv)	[21, 23]
1994	CP	4-Glutathionylcyclophosphamide  Monochloromonoglutathionyl phosphoramidate mustard	Incubation of 4-hydroxy- cyclophosphamide with GSTs and GSH Incubation of phosphoramidate mustard with GST A1-1 and GSH	[52]
1995	IF	2-Chloroethylamine 1,3-Oxazolidin-2-one	Human (iv)	[17]
1995	IF	Isophosphoramidate mustard Carboxyifosfamide 2-Dechloroethylifosfamide 3-Dechloroethylifosfamide 4-Oxoifosfamide	Human [adults] (iv)	[25]
1995	IF	Isophosphoramidate mustard Aldoifosfamide [NO 4-glutathionyl ifosfamide]  Monoglutathionyl isophosphoramidate mustard Diglutathionyl isophosphoramidate mustard	Incubation of 4- hydroxyifosfamide with GSH  Incubation of isophosphoramidate mustard with GST P1-1 and GSH	[14]
1995	IF	Isophosphoramidate mustard 2-Dechloroethylifosfamide 3-Dechloroethylifosfamide Alcoifosfamide 4-Hydroxy-2-dechloroethyl-ifosfamide 4-Hydroxy-3-dechloroethyl-ifosfamide N-Dechloroethylisophosphoramidate mustard 2,3-Didechloroethylifosfamide	Rat (iv)	[64]
1995	CP	Carboxyphosphamide Dechloroethylcyclophosphamide 4-Oxocyclophosphamide	Human [children] (iv)	[65]
1996	acrolein	3-Hydroxypropylmercapturic acid 2-Carboxyethylmercapturic acid	Rat (inhalation) Rat (ip)	[66]

1998	IF	2-Chloroethylamine 2-Dechloroethylifosfamide 3-Dechloroethylifosfamide	Human (po and iv)	[67]
------	----	--	-------------------	------

---

Accepted Manuscript

**Table 2**

IF metabolites ions identified in the LC-MS-based metabolomic analysis of urine samples from IF-treated mice.

Symbol	Rt (min)	$m/z$ (ESI+)	Formula	Mass Error (ppm)	Identity	Peak area (Mean $\pm$ SD)
F1	4.36	261.0322	C <sub>7</sub> H <sub>15</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>2</sub> P	-1.5	Ifosfamide	836.0 $\pm$ 357.0
F2	2.42	199.0405	C <sub>5</sub> H <sub>12</sub> ClN <sub>2</sub> O <sub>2</sub> P	1.0	2-Dechloroethylifosfamide	529.0 $\pm$ 272.5
F3	2.14	199.0403	C <sub>5</sub> H <sub>12</sub> ClN <sub>2</sub> O <sub>2</sub> P	0.0	3-Dechloroethylifosfamide	472.2 $\pm$ 238.7
F4	3.33	293.0221	C <sub>7</sub> H <sub>15</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>4</sub> P	-1.4	Carboxylifosfamide	370.8 $\pm$ 107.9
F5	3.20	259.0171	C <sub>7</sub> H <sub>13</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>2</sub> P	0.4	Iminoifosfamide	113.4 $\pm$ 43.9
F6	3.51	279.0377	C <sub>7</sub> H <sub>17</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>3</sub> P	-19.7	Alcoifosfamide	92.6 $\pm$ 53.4
F7	3.32	275.0170	C <sub>7</sub> H <sub>13</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>3</sub> P	18.5	4-Ketoifosfamide	74.6 $\pm$ 18.4
F8	3.16	277.0272	C <sub>7</sub> H <sub>15</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>3</sub> P	-1.4	Aldoifosfamide	11.2 $\pm$ 2.2
F9	1.69	221.0014	C <sub>4</sub> H <sub>11</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>2</sub> P	0.5	Ifosforamide mustard	17.4 $\pm$ 8.2
F10	2.78	277.0270	C <sub>7</sub> H <sub>15</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>3</sub> P	-2.2	4-Hydroxyifosfamide	37.4 $\pm$ 12.3
F11	3.47	453.0584	C <sub>13</sub> H <sub>23</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>9</sub> P	-2.6	4-Hydroxyifosfamide glucuronide	1.5 $\pm$ 1.0

**Table 3**

CP metabolite ions identified in the LC-MS-based metabolomic analysis of urine samples from CP-treated mice.

Symbol	Rt (min)	<i>m/z</i> ( ESI+)	Formula	Mass Error (ppm)	Identity	Peak area (Mean ± SD)
P1	4.53	261.0333	C <sub>7</sub> H <sub>15</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>2</sub> P	2.7	Cyclophosphamide	1047.2 ± 311.5
P2	3.57	293.0227	C <sub>7</sub> H <sub>15</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>4</sub> P	0.7	Carboxyphosphamide	2105.4 ± 416.9
P3	2.42	199.0405	C <sub>5</sub> H <sub>12</sub> ClN <sub>2</sub> O <sub>2</sub> P	1.0	Dechloroethylcyclophosphamide	333.6 ± 68.3
P4	3.81	277.0267	C <sub>7</sub> H <sub>15</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>3</sub> P	-3.2	Aldophosphamide	7.6 ± 3.2
P5	3.73	279.0437	C <sub>7</sub> H <sub>17</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>3</sub> P	1.8	Alcophosphamide	251.8 ± 27.8
P6	3.20	259.0171	C <sub>7</sub> H <sub>13</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>2</sub> P	0.4	Iminocyclophosphamide	31.8 ± 7.7
P7	3.32	221.0019	C <sub>4</sub> H <sub>11</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>2</sub> P	2.7	Phosphamide mustard	7.6 ± 4.4
P8	3.01	277.0279	C <sub>7</sub> H <sub>15</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>3</sub> P	1.1	4-Hydroxycyclophosphamide	7.6 ± 2.4
P9	3.19	455.0781	C <sub>13</sub> H <sub>25</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>9</sub> P	2.6	Alcophosphamide glucuronide	5.8 ± 1.5
P10	3.58	275.0100	C <sub>7</sub> H <sub>13</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>3</sub> P	-6.9	4-Ketocyclophosphamide	455.8 ± 69.3
P11	1.83	213.0198	C <sub>5</sub> H <sub>10</sub> ClN <sub>2</sub> O <sub>3</sub> P	0.9	Dechloroethylketocyclophosphamide	117.2 ± 24.3
P12	1.86	217.0511	C <sub>5</sub> H <sub>14</sub> ClN <sub>2</sub> O <sub>3</sub> P	0.9	Dechloroethylalcophosphamide	23.2 ± 3.8

**Table 4**

Major metabolic reactions and corresponding metabolites in mouse urine following treatment with IF and CP.

Metabolic reaction	IF	CP
Unchanged drug	F1	P1
Dechloroethylation	F2, F3	P2, P11, P12
Hydroxylation	F11	P8
Ketonization	F7	P10
Desaturation	F5	P6
$\beta$ -Elimination of acrolein	F9	P7
Ring-opening	F4, F6, F8	P2, P4, P5
Glucuronic acid conjugation	F11	P9

Accepted Manuscript








Figure 2








Figure 4










Figure 5









Manuscript

